---

Advertising Information | FAQs | About Us | Contact Us | Privacy Policy

---

---

This year is proving to be a critical one for many industries, including the pharma-ceutical industry. The results of the 2008 presidential election, the economy, and sweeping changes in the global market place all factor into how leaders in the industry will either falter or thrive. Actionable, evidence-based and global pharmaceutical competitive intelligence (CI) and general business intelligence (BI) will play an important role in the drama about to unfold. The pressing issues facing pharma CI were addressed in-depth at the 2008 Pharmaceutical Competitive Intelligence Conference where approximately 240 attendees got to hear excellent information on the state of CI within the life sciences, and interesting suggestions as to where the discipline is headed. This article highlights several presentations made at this conference and discusses some common themes, including how environments for the pharmaceutical and device industries are changing dramatically with implications for CI going forward, the importance of keeping an eye on China, and whether CI is a strategic or tactical discipline. Topic headings include: Innovation Proven by Value Softening of Medical Device Pipeline Keeping China in Sight Global CI Role Table: Challenges and Downsides of Emerging Markets and Countries Insert: Big Pharma Ranks China as Number One Destination in Asia for Pharmaceutical Outsourcing China's Strengths and Weaknesses< Is There a Balance between Strategic CI and Tactical CI?

Order and pay for this reprint now using your credit card...

ONLY $6.95
Download PDF file immediately after paying:

PMN78-03
Issue: Vol. 7, No. 8: October 2008
Word Count: 2566

Find other articles in related Topic Areas:

• Strategic Marketing & Planning